130 related articles for article (PubMed ID: 14644522)
1. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model.
Liu J; Tsao MS; Pagura M; Shalinsky DR; Khoka R; Fata J; Johnston MR
Lung Cancer; 2003 Dec; 42(3):335-44. PubMed ID: 14644522
[TBL] [Abstract][Full Text] [Related]
2. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
3. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
Bissett D; O'Byrne KJ; von Pawel J; Gatzemeier U; Price A; Nicolson M; Mercier R; Mazabel E; Penning C; Zhang MH; Collier MA; Shepherd FA
J Clin Oncol; 2005 Feb; 23(4):842-9. PubMed ID: 15681529
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.
Littlepage LE; Sternlicht MD; Rougier N; Phillips J; Gallo E; Yu Y; Williams K; Brenot A; Gordon JI; Werb Z
Cancer Res; 2010 Mar; 70(6):2224-34. PubMed ID: 20215503
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy.
Behrendt CE; Ruiz RB
Thromb Haemost; 2003 Oct; 90(4):734-7. PubMed ID: 14515196
[TBL] [Abstract][Full Text] [Related]
8. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model.
Ozerdem U; Mach-Hofacre B; Varki N; Folberg R; Mueller AJ; Ochabski R; Pham T; Appelt K; Freeman WR
Curr Eye Res; 2002 Feb; 24(2):86-91. PubMed ID: 12187478
[TBL] [Abstract][Full Text] [Related]
9. Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340).
Foda HD; Rollo EE; Drews M; Conner C; Appelt K; Shalinsky DR; Zucker S
Am J Respir Cell Mol Biol; 2001 Dec; 25(6):717-24. PubMed ID: 11726397
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
Douillard JY; Peschel C; Shepherd F; Paz-Ares L; Arnold A; Davis M; Tonato M; Smylie M; Tu D; Voi M; Humphrey J; Ottaway J; Young K; Vreckem AV; Seymour L
Lung Cancer; 2004 Dec; 46(3):361-8. PubMed ID: 15541822
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model.
Alves F; Borchers U; Padge B; Augustin H; Nebendahl K; Klöppel G; Tietze LF
Cancer Lett; 2001 Apr; 165(2):161-70. PubMed ID: 11275365
[TBL] [Abstract][Full Text] [Related]
12. Validation of an orthotopic model of human lung cancer with regional and systemic metastases.
Johnston MR; Mullen JB; Pagura ME; Howard RB
Ann Thorac Surg; 2001 Apr; 71(4):1120-5. PubMed ID: 11308147
[TBL] [Abstract][Full Text] [Related]
13. Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.
El Bradey M; Cheng L; Bartsch DU; Appelt K; Rodanant N; Bergeron-Lynn G; Freeman WR
J Ocul Pharmacol Ther; 2004 Jun; 20(3):217-36. PubMed ID: 15279727
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
15. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
16. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
Heath EI; Burtness BA; Kleinberg L; Salem RR; Yang SC; Heitmiller RF; Canto MI; Knisely JP; Topazian M; Montgomery E; Tsottles N; Pithavala Y; Rohmiller B; Collier M; Forastiere AA
Invest New Drugs; 2006 Mar; 24(2):135-40. PubMed ID: 16502351
[TBL] [Abstract][Full Text] [Related]
17. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases.
Scatena R
Expert Opin Investig Drugs; 2000 Sep; 9(9):2159-65. PubMed ID: 11060800
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor Prinomastat.
Wiart M; Fournier LS; Novikov VY; Shames DM; Roberts TP; Fu Y; Shalinsky DR; Brasch RC
Technol Cancer Res Treat; 2004 Aug; 3(4):377-82. PubMed ID: 15270589
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
[TBL] [Abstract][Full Text] [Related]
20. Angelica sinensis suppresses human lung adenocarcinoma A549 cell metastasis by regulating MMPs/TIMPs and TGF-β1.
Gao M; Zhang JH; Zhou FX; Xie CH; Han G; Fang SQ; Zhou YF
Oncol Rep; 2012 Feb; 27(2):585-93. PubMed ID: 22076386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
